Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
08:32am, Monday, 13'th Sep 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript
11:11am, Thursday, 12'th Aug 2021
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
04:30pm, Wednesday, 11'th Aug 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
08:12am, Thursday, 05'th Aug 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
New Strong Sell Stocks for July 21st
10:50am, Wednesday, 21'st Jul 2021
CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.
Moving Average Crossover Alert: DiaMedica Therapeutics (DMAC)
07:45am, Wednesday, 14'th Jul 2021
DiaMedica Therapeutics (DMAC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients
09:14am, Tuesday, 29'th Jun 2021
DiaMedica Therapeutics Inc (NASDAQ: DMAC) has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD). The trial is designed to evaluate the effec
DMAC Stock Price Falls Over 25% Pre-Market: Why It Happened
08:59am, Tuesday, 29'th Jun 2021
The stock price of DiaMedica Therapeutics Inc (NASDAQ: DMAC) fell by over 25% pre-market. This is why it happened.
DiaMedica: Undercovered Stroke Drug Company With Decent Data
12:47pm, Sunday, 13'th Jun 2021
DiaMedica produced decent stroke data last year for DM199. The company does not have a lot of cash.
Is the Options Market Predicting a Spike in DiaMedica (DMAC) Stock?
09:01am, Wednesday, 26'th May 2021
Investors need to pay close attention to DiaMedica (DMAC) stock based on the movements in the options market lately.
DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke
12:28pm, Monday, 17'th May 2021
The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrei
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2021 Results - Earnings Call Transcript
04:31pm, Sunday, 09'th May 2021
DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2021 Results - Earnings Call Transcript
New Strong Sell Stocks for April 20th
10:32am, Tuesday, 20'th Apr 2021
ATTO, DMAC, DG, GEL, and IAG have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2021
DiaMedica Therapeutics to Present Research at the National Kidney Foundation's 2021 Spring Clinical Meetings
08:14am, Monday, 05'th Apr 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
